Allergy · Nasal SprayRegulatory Approvalregulatorymid-term

FDA Grants AP Status for Azelastine Hydrochloride and Fluticasone Propionate

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/23/2026, 12:31:50 AM

Assessment confidence: 65% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's grant of Abbreviated Approval for a combination nasal spray positions Padagis Israel to strengthen its market presence in the allergy segment. This development necessitates a strategic review of competitive dynamics and pricing strategies within the portfolio. Regulatory context from FDA (FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)) supports the near-term read. Assessment grounded in 20 ranked evidence items (9 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market share and pricing strategies in the allergy segment. The strongest clinical anchor is Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia (ClinicalTrials.gov), moderate corpus alignment. In Allergy · Nasal Spray, 8 regulatory and 3 competitive items passed relevance filtering for Azelastine Hydrochloride.

Competitive Pressure

The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Approval for Tofacitinib Citrate (ANDA217298). This approval may enhance Padagis Israel's position in the allergy treatment market, competing with existing nasal spray products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL) (FDA). Entity match (azelastine hydrochloride); Regulatory pathway relevance (nda). The Abbreviated Approval status indicates a streamlined pathway for market entry, which may influence compliance and labeling strategies for competing products.

Key Risks

Elevated medium regulatory exposure for Azelastine Hydrochloride could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (BPL-1357 Against H1N1 Influenza Virus Challenge) could weigh on Azelastine Hydrochloride through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The approval could lead to increased market share for Padagis Israel, potentially affecting pricing and revenue for existing competitors in the allergy treatment market.
Portfolio teams should assess the impact of this approval on market share and pricing strategies in the allergy segment.

What Would Change This Assessment

This becomes more urgent if Monitor for market entry timelines and potential competitor responses to this approval.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE (SUPPL)
FDAhigh relevance
Entity match (azelastine hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPRENORPHINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RILPIVIRINE HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SOTALOL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ALFUZOSIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Validate the Effect of Calcium Oral Spray on Early Childhood Caries
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Intranasal Insulin for Posttraumatic Stress Disorder
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
BPL-1357 Against H1N1 Influenza Virus Challenge
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Menstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Tofacitinib Citrate (ANDA217298)
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Tofacitinib Citrate ANDA220137
Humanexa Signalsmedium relevance
Moderate corpus alignment

Warm intranasal saline irrigation reduces intraoperative blood loss during functional endoscopic sinus surgery: a propensity score-matched cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Azelastine Hydrochloride
Fluticasone Propionate
allergy treatment market

Commercial impact

medium

The approval could lead to increased market share for Padagis Israel, potentially affecting pricing and revenue for existing competitors in the allergy treatment market.

Regulatory impact

medium

The Abbreviated Approval status indicates a streamlined pathway for market entry, which may influence compliance and labeling strategies for competing products.

What to watch

Monitor for market entry timelines and potential competitor responses to this approval.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.